Source: Eur Respir J 2010; 35: 606-613
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Chang K. C, Leung C. C, Yew W. W, Lau T. Y, Leung W. M, Tam C. M, Lam H. C, Tse P. S, Wong M. Y, Lee S. N, Wat K. I, Ma Y. H.. Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis?. Eur Respir J 2010; 35: 606-613

Member's Comments

No comment yet.

Related content which might interest you: Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Source: Eur Respir J 2008; 31: 904-905 Year: 2008 Protecting the tuberculosis drug pipeline: stating the case for the rational use of fluoroquinolones}, Source: Eur Respir J 2012; 40: 814-822 Year: 2012 Paradoxical reactions in non-HIV tuberculosis presenting as endobronchial obstruction Source: Eur Respir Rev 2009; 18: 295-299 Year: 2009 Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016 Macrolides and lower respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=78 Year: 2004 Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary? Source: Eur Respir J, 54 (4) 1901494; 10.1183/13993003.01494-2019 Year: 2019 Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis Source: Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020 Year: 2021 Potential antibiotic resistant pathogens in community-acquired pneumonia: playing it safe is anything but Source: Eur Respir J, 54 (1) 1900870; 10.1183/13993003.00870-2019 Year: 2019 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Are antimicrobials still the future of respiratory infection therapy? Source: Virtual Congress 2021 – Emerging data for the management of respiratory tract infections Year: 2021 Could the initial use of antipseudomonal agents improve the prognosis for non-hospital acquired pneumonia? Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections Source: Eur Respir J 2002; 20: 3S-8S Year: 2002 Bacterial agents of community-acquired lower respiratory tract infections: observational study on antimicrobial drugs susceptibility Source: Eur Respir J 2002; 20: Suppl. 38, 421s Year: 2002 Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2014; 43: 884-897 Year: 2014 Treatment by linezolid of lung TB caused by drug resistant mycobacterium (MBT) Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis Source: Eur Respir J 2015; 46: 444-455 Year: 2015 What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis? Source: Eur Respir J 2009; 34: 1492-1494 Year: 2009 Future antibiotics and current practices for treating respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=255 Year: 2004